aminocaproic acid has been researched along with Subarachnoid Hemorrhage in 55 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm." | 9.04 | Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. ( Chandra, B, 1978) |
| "5 g of epsilon-aminocaproic acid (EACA) per hour after subarachnoid hemorrhage (SAH) from an intracranial aneurysm." | 7.67 | Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. ( Bakay, RA; Burchiel, KJ; Hoffman, JM, 1984) |
| "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH)." | 7.66 | Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. ( Benjamin, SP; Dohn, DE; Tubbs, RR, 1979) |
| "ε-Aminocaproic acid (EACA) has been used to reduce the rate of cerebral aneurysm rerupture before definitive treatment." | 5.38 | ε-Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients. ( Barrow, DL; Cawley, CM; Hui, FK; Lieber, M; Moskowitz, SI; Schuette, AJ; Spiotta, AM, 2012) |
| "A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm." | 5.04 | Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. ( Chandra, B, 1978) |
| "We sought trials or observational studies of ≥20 adults involving any antifibrinolytic drug (TXA, epsilonaminocaproic acid (EACA) or aprotinin) for spontaneous (non-traumatic, non-surgical/iatrogenic), non-heamophiliac bleeding." | 4.88 | The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. ( Al-Shahi Salman, R; Ross, J, 2012) |
| "Long-term administration of the antifibrinolytic agent epsilon aminocaproic acid (EACA) reduces the rate of rehemorrhage in patients with aneurysmal subarachnoid hemorrhage (SAH), but is associated with cerebral ischemia." | 3.76 | Short-term antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: effects on rehemorrhage, cerebral ischemia, and hydrocephalus. ( Ardelt, AA; Fisher, WS; Harrigan, MR; Rajneesh, KF, 2010) |
| "epsilon-Aminocaproic acid (EACA) is an antifibrinolytic agent used to prevent rebleeding in aneurysmal subarachnoid hemorrhage." | 3.74 | Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. ( Chwajol, M; Connolly, ES; Ducruet, AF; Fernandez, A; Hahn, DK; Hickman, ZL; Kellner, CP; Kim, GH; Komotar, RJ; Mayer, SA; Otten, ML; Starke, RM, 2008) |
| "5 g of epsilon-aminocaproic acid (EACA) per hour after subarachnoid hemorrhage (SAH) from an intracranial aneurysm." | 3.67 | Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. ( Bakay, RA; Burchiel, KJ; Hoffman, JM, 1984) |
| "The incidence and severity of cerebral vasospasm and hydrocephalus following induced subarachnoid hemorrhage in an experimental group of animals that subsequently received epsilon-aminocaproic acid was compared to that seen in a control group that received no antifibrinolytic therapy." | 3.67 | An experimental study of the influence of antifibrinolytic therapy on post-subarachnoid-hemorrhagic cerebral vasospasm and hydrocephalus. ( Dujovny, M; Heros, RC; Kenning, JA; Latchaw, RE; Nelson, D, 1984) |
| "We previously reported that epsilon-aminocaproic acid (EACA) prolonged the bleeding time in patients with intracranial aneurysms when given in doses of 36 to 48 gm/day." | 3.67 | Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. ( Atkinson, AJ; Cerullo, L; Cohen, I; Green, D; Ruo, TI; Ts'ao, CH, 1985) |
| "Patients suffering from a subarachnoid hemorrhage who were admitted to the Neurosurgical Unit of the Royal Perth Hospital during the period 1971 to 1979 were assessed with regard to the effectiveness of preoperative treatment with epsilon-aminocaproic acid, kanamycin, and reserpine." | 3.66 | Medical management of patients following a ruptured cerebral aneurysm, with epsilon-aminocaproic acid, kanamycin, and reserpine. ( Knuckey, NW; Stokes, BA, 1982) |
| "One hundred consecutive patients treated with epsilon aminocaproic acid 24 grams daily prior to surgery for ruptured intracranial aneurysms have been compared with the previous 100 patients managed similarly but without anti-fibrinolytic drugs." | 3.66 | Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. ( Ameen, AA; Illingworth, R, 1981) |
| "A rapid fluorometric assay technique has been utilized to assess the degree of fibrinolytic inhibition in 20 patients with ruptured intracranial aneurysms treated with epsilon-aminocaproic acid (EACA)." | 3.66 | A method for monitoring antifibrinolytic therapy in patients with ruptured intracranial aneurysms. ( Burchiel, KJ; Schmer, G, 1981) |
| "Amicar (epsilon-aminocaproic acid) has been used in patients with subarachnoid hemorrhage to promote clotting." | 3.66 | Cerebral thrombosis associated with Amicar therapy. ( Hoffman, EP; Koo, AH, 1979) |
| "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH)." | 3.66 | Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. ( Benjamin, SP; Dohn, DE; Tubbs, RR, 1979) |
| "10 patients suffering from intracranial aneurysm causing subarachnoid hemorrhage (SAH) have been treated during the acute pre-and postoperatory phase with omega-aminocaproic acid." | 3.66 | Fibrinolytic activity in blood and cerebrospinal fluid in subarachnoid hemorrhage from ruptured intracranial saccular aneurysm before and during EACA treatment. ( Collice, M; D'angelo, V; Donati, MB; Ferrara, M; Filizzolo, F; Porta, M, 1978) |
| "The association of myopathy with epsilon-aminocaproic acid (EACA) treatment after subarachnoid hemorrhage in two cases is reported." | 3.66 | Myopathy associated with epsilon-aminocaproic acid (EACA) therapy. Report of two cases. ( MacKay, AR; Sang U, H; Weinstein, PR, 1978) |
| "ε-Aminocaproic acid (EACA) has been used to reduce the rate of cerebral aneurysm rerupture before definitive treatment." | 1.38 | ε-Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients. ( Barrow, DL; Cawley, CM; Hui, FK; Lieber, M; Moskowitz, SI; Schuette, AJ; Spiotta, AM, 2012) |
| "The incidence of hydrocephalus or symptomatic vasospasm was not unduly elevated in patients receiving preoperative EACA." | 1.30 | Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. ( Horner, TG; Leipzig, TJ; Redelman, K, 1997) |
| "Ten cases of subarachnoid hemorrhage (SAH) from ruptured cerebral aneurysm are reported." | 1.27 | Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products. ( McLaurin, RL; Perrotta, G; Sawaya, R; Sonnino, V, 1983) |
| "An increased incidence of communicating hydrocephalus following subarachnoid hemorrhage has been observed on the neurosurgical service at Vanderbilt University Hospital during the past four years." | 1.26 | Spontaneous subarachnoid hemorrhage complicated by communicating hydrocephalus: epsilon amino caproic acid as a possible predisposing factor. ( Park, BE, 1979) |
| " The last 20 patients of the present series have been treated with very low doses of AMCA associated with parotid kallikrein inhibitor (Trasylol); this dosage has been effective in preventing recurrence and has appeared to be freer from severe side effects." | 1.26 | The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. ( Schisano, G, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (70.91) | 18.7374 |
| 1990's | 2 (3.64) | 18.2507 |
| 2000's | 1 (1.82) | 29.6817 |
| 2010's | 13 (23.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, HG | 1 |
| Cha, BG | 1 |
| Kang, DW | 1 |
| Kim, DY | 1 |
| Ki, SK | 1 |
| Kim, SI | 1 |
| Han, JH | 1 |
| Yang, W | 1 |
| Kim, CK | 1 |
| Kim, J | 1 |
| Lee, SH | 1 |
| Baranoski, JF | 1 |
| Ducruet, AF | 2 |
| Baharoglu, MI | 1 |
| Germans, MR | 2 |
| Rinkel, GJ | 1 |
| Algra, A | 1 |
| Vermeulen, M | 1 |
| van Gijn, J | 1 |
| Roos, YB | 1 |
| Eastin, TR | 1 |
| Snipes, CD | 1 |
| Seupaul, RA | 1 |
| Foreman, PM | 1 |
| Chua, M | 1 |
| Harrigan, MR | 2 |
| Fisher, WS | 2 |
| Tubbs, RS | 1 |
| Shoja, MM | 1 |
| Griessenauer, CJ | 1 |
| Malekpour, M | 1 |
| Kulwin, C | 1 |
| Bohnstedt, BN | 1 |
| Radmand, G | 1 |
| Sethia, R | 1 |
| Mendenhall, SK | 1 |
| Weyhenmeyer, J | 1 |
| Hendricks, BK | 1 |
| Leipzig, T | 1 |
| Payner, TD | 1 |
| Shah, MV | 1 |
| Scott, J | 1 |
| DeNardo, A | 1 |
| Sahlein, D | 1 |
| Cohen-Gadol, AA | 1 |
| Post, R | 1 |
| Coert, BA | 1 |
| Vandertop, WP | 1 |
| Verbaan, D | 1 |
| Starke, RM | 1 |
| Kim, GH | 1 |
| Fernandez, A | 1 |
| Komotar, RJ | 1 |
| Hickman, ZL | 1 |
| Otten, ML | 1 |
| Kellner, CP | 1 |
| Hahn, DK | 1 |
| Chwajol, M | 1 |
| Mayer, SA | 1 |
| Connolly, ES | 1 |
| Rajneesh, KF | 1 |
| Ardelt, AA | 1 |
| Nina, P | 2 |
| Schisano, G | 3 |
| Thomas, G | 1 |
| Evelyne, E | 1 |
| Hui, FK | 2 |
| Schuette, AJ | 2 |
| Lieber, M | 1 |
| Spiotta, AM | 1 |
| Moskowitz, SI | 1 |
| Barrow, DL | 2 |
| Cawley, CM | 2 |
| Ross, J | 1 |
| Al-Shahi Salman, R | 1 |
| Obuchowski, NA | 1 |
| Walkup, RR | 1 |
| Samuels, OB | 1 |
| Spallone, A | 1 |
| Solomon, RA | 1 |
| Post, KD | 1 |
| McMurtry, JG | 1 |
| Burchiel, KJ | 2 |
| Hoffman, JM | 1 |
| Bakay, RA | 1 |
| Rosenwasser, RH | 1 |
| Buchheit, WA | 1 |
| Truex, RC | 1 |
| Galassi, G | 1 |
| Gibertoni, M | 1 |
| Corradini, L | 1 |
| Colombo, A | 1 |
| Kenning, JA | 1 |
| Heros, RC | 1 |
| Dujovny, M | 1 |
| Latchaw, RE | 1 |
| Nelson, D | 1 |
| Sawaya, R | 1 |
| Sonnino, V | 1 |
| McLaurin, RL | 1 |
| Perrotta, G | 1 |
| Yamaura, A | 1 |
| Nakamura, T | 1 |
| Makino, H | 1 |
| Hagihara, Y | 1 |
| Smith, RR | 1 |
| Ramirez-Lassepas, M | 1 |
| Chowdhary, UM | 2 |
| Sayed, K | 1 |
| Fodstad, H | 1 |
| Knuckey, NW | 1 |
| Stokes, BA | 1 |
| Vanneste, JA | 1 |
| van Wijngaarden, GK | 1 |
| Ameen, AA | 1 |
| Illingworth, R | 1 |
| Glick, R | 1 |
| Green, D | 2 |
| Ts'ao, C | 1 |
| Witt, WA | 1 |
| Yu, AT | 1 |
| Raimondi, AJ | 1 |
| Britt, CW | 1 |
| Light, RR | 1 |
| Peters, BH | 1 |
| Schochet, SS | 1 |
| Alvarez Garijo, JA | 1 |
| Vilches, JJ | 1 |
| Aznar, JA | 1 |
| Shucart, WA | 1 |
| Hussain, SK | 1 |
| Cooper, PR | 1 |
| Biswas, CK | 1 |
| Milligan, DA | 1 |
| Agte, SD | 1 |
| Kenward, DH | 1 |
| Tilley, PJ | 1 |
| Brodkin, HM | 1 |
| Schmer, G | 1 |
| Levati, A | 1 |
| Minella, C | 1 |
| Farina, ML | 1 |
| D'Angelo, V | 2 |
| Leipzig, TJ | 1 |
| Redelman, K | 1 |
| Horner, TG | 1 |
| Carey, PC | 1 |
| Hussein, MM | 1 |
| Wintzen, AR | 1 |
| Van Rossum, J | 1 |
| Chandra, B | 1 |
| Hoffman, EP | 1 |
| Koo, AH | 1 |
| Tubbs, RR | 1 |
| Benjamin, SP | 1 |
| Dohn, DE | 1 |
| Park, BE | 1 |
| Peerless, SJ | 1 |
| Filizzolo, F | 1 |
| Collice, M | 1 |
| Ferrara, M | 1 |
| Donati, MB | 1 |
| Porta, M | 1 |
| MacKay, AR | 1 |
| Sang U, H | 1 |
| Weinstein, PR | 1 |
| White, RP | 1 |
| Robertson, JT | 1 |
| Ts'ao, CH | 1 |
| Cerullo, L | 1 |
| Cohen, I | 1 |
| Ruo, TI | 1 |
| Atkinson, AJ | 1 |
| Biller, J | 1 |
| Godersky, JC | 1 |
| Adams, HP | 1 |
| Rehák, S | 1 |
| Kadanka, Z | 1 |
| Novotný, O | 1 |
| Penka, M | 1 |
| Ruelle, A | 1 |
| Lasio, G | 1 |
| Boccardo, M | 1 |
| Gottlieb, A | 1 |
| Severi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study[NCT01996436] | Phase 4 | 330 participants (Anticipated) | Interventional | 2016-08-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for aminocaproic acid and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.
Topics: Administration, Oral; Aminocaproic Acid; Antifibrinolytic Agents; Brain Ischemia; Confidence Interva | 2013 |
The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Hemorrhage; Humans; Middle Aged; | 2012 |
Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm.
Topics: Aminocaproates; Aminocaproic Acid; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Ruptu | 1981 |
Antifibrinolytic treatment in subarachnoid haemorrhage: present state.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Antifibrinolytic Agents; Clinical Trials as Topic; Humans; R | 1982 |
5 trials available for aminocaproic acid and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
EACA and subarachnoid hemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Humans; Recurrence; Subarachnoid Hemorr | 1981 |
Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage.
Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Cyclohexanecarboxyli | 1981 |
Antifibrinolytic treatment in subarachnoid haemorrhage: present state.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Antifibrinolytic Agents; Clinical Trials as Topic; Humans; R | 1982 |
Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Arteriovenous Fistula; Basilar Artery; C | 1979 |
Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial.
Topics: Adult; Aged; Aminocaproic Acid; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind | 1978 |
47 other studies available for aminocaproic acid and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Ceria Nanoparticles Synthesized With Aminocaproic Acid for the Treatment of Subarachnoid Hemorrhage.
Topics: Aminocaproic Acid; Animals; Anti-Inflammatory Agents; Brain; Brain Edema; Cell Death; Cerium; In Sit | 2018 |
Nanoparticle-Facilitated Delivery of Antioxidant Therapy following Aneurysmal Subarachnoid Hemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Antioxidants; Humans; Nanoparticles; Subarachnoid Hemorrhage | 2019 |
Are antifibrinolytic agents effective in the treatment of aneurysmal subarachnoid hemorrhage?
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Humans; Subarachnoid Hemorrhage; Tranexamic Acid | 2014 |
Antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage increases the risk for deep venous thrombosis: A case-control study.
Topics: Adult; Aged; Aminocaproic Acid; Aneurysm, Ruptured; Angiography, Digital Subtraction; Antifibrinolyt | 2015 |
Effect of short-term ε-aminocaproic acid treatment on patients undergoing endovascular coil embolization following aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Aminocaproic Acid; Aneurysm, Ruptured; Antifibrinolytic Agents; Cohort Studies; Drug Ad | 2017 |
Letter to the Editor: Short-term ε-aminocaproic acid treatment and endovascular coil embolization.
Topics: Aminocaproic Acid; Blood Vessel Prosthesis; Humans; Subarachnoid Hemorrhage | 2017 |
Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage.
Topics: Acute Disease; Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Clinical Protocols; Drug Adm | 2008 |
Short-term antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: effects on rehemorrhage, cerebral ischemia, and hydrocephalus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Brain Ischem | 2010 |
Antifibrinolytic drugs in subarachnoid hemorrhage by ruptured aneurysms.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Brain Ischemia; Female; Humans; Hydrocephalus; Male; Sub | 2011 |
Antifibrinolytic in subarachnoid hemorrhage.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Brain Ischemia; Female; Humans; Hydrocephalus; Male; Sub | 2011 |
ε-Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Brain Ischemia; Case-Control Studies; Cerebral An | 2012 |
An examination of aneurysm rerupture rates with epsilon aminocaproic acid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Aneurysm, Ruptured; Antifibrinolytic | 2013 |
Antifibrinolytics in aneurysmal subarachnoid haemorrhage. A retrospective comparison of two different forms of antifibrinolytic therapy.
Topics: Adult; Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Drug Therapy, Combinat | 1982 |
Depression of circulating blood volume in patients after subarachnoid hemorrhage: implications for the management of symptomatic vasospasm.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Volume; Cerebral Angiography; Dexamet | 1984 |
Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Cerebral Arteries; Depression, Chemical; | 1984 |
Management of subarachnoid hemorrhage.
Topics: Adolescent; Adult; Aminocaproic Acid; Antihypertensive Agents; Child; Cimetidine; Dexamethasone; Hum | 1984 |
Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.
Topics: Aged; Aminocaproates; Aminocaproic Acid; Biopsy; Female; Humans; Muscles; Muscular Diseases; Necrosi | 1983 |
An experimental study of the influence of antifibrinolytic therapy on post-subarachnoid-hemorrhagic cerebral vasospasm and hydrocephalus.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Cerebral Angiography; Cerebral Hemorrhage; Hydrocephalus | 1984 |
Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products.
Topics: Adult; Aged; Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Female; Fibrin Fibrinogen D | 1983 |
Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Animal experiment and a review of literature.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Blood Pressure; Cerebral Cortex; Cisterna Magna; Cyclohe | 1980 |
Medical management of patients following a ruptured cerebral aneurysm, with epsilon-aminocaproic acid, kanamycin, and reserpine.
Topics: Aminocaproates; Aminocaproic Acid; Drug Therapy, Combination; Female; Humans; Intracranial Aneurysm; | 1982 |
Epsilon-aminocaproic acid myopathy. Report of a case and literature review.
Topics: Adult; Aminocaproates; Aminocaproic Acid; Biopsy; Electromyography; Humans; Male; Muscles; Myoglobin | 1982 |
Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Child; Female; | 1981 |
High does epsilon-aminocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage.
Topics: Adult; Aged; Aminocaproates; Aminocaproic Acid; Bleeding Time; Blood Coagulation; Female; Humans; In | 1981 |
Rhabdomyolysis during treatment with epsilon-aminocaproic acid.
Topics: Adult; Aminocaproates; Aminocaproic Acid; Female; Humans; Muscles; Muscular Diseases; Myoglobinuria; | 1980 |
Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity.
Topics: Aminocaproic Acid; Cyclohexanecarboxylic Acids; Fibrin Fibrinogen Degradation Products; Humans; Intr | 1980 |
Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial.
Topics: Aminocaproates; Aminocaproic Acid; Drug Evaluation; Humans; Intracranial Aneurysm; Recurrence; Subar | 1980 |
Acute renal failure and myopathy after treatment with aminocaproic acid.
Topics: Acute Kidney Injury; Adult; Aminocaproates; Aminocaproic Acid; Aspartate Aminotransferases; Creatine | 1980 |
Myoglobinuria following epsilon-aminocaproic acid (EACA) therapy. Case report.
Topics: Aminocaproates; Aminocaproic Acid; Female; Humans; Middle Aged; Myoglobinuria; Subarachnoid Hemorrha | 1980 |
A method for monitoring antifibrinolytic therapy in patients with ruptured intracranial aneurysms.
Topics: Aminocaproates; Aminocaproic Acid; Humans; Injections, Intravenous; Intracranial Aneurysm; Plasminog | 1981 |
Potential hazards of antifibrinolytic treatment in subarachnoid haemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Coronary Disease; Humans; Male; Middle Aged; Pulmonary Embolism; | 1980 |
Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Aneurysm, Ruptured; Antifibrinolytic Agents; Huma | 1997 |
Antifibrinolytic therapy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Humans; Recurrence; Subarachnoid Hemorrhage; Tranexamic | 1997 |
epsilon-aminocaproic acid in prevention of subarachnoid haemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Drug Evaluation; Humans; Subarachnoid Hemorrhage | 1979 |
Cerebral thrombosis associated with Amicar therapy.
Topics: Adult; Aminocaproates; Aminocaproic Acid; Cerebral Angiography; Female; Humans; Intracranial Embolis | 1979 |
Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report.
Topics: Acute Disease; Aged; Aminocaproates; Aminocaproic Acid; Female; Humans; Recurrence; Renal Artery; Su | 1979 |
Spontaneous subarachnoid hemorrhage complicated by communicating hydrocephalus: epsilon amino caproic acid as a possible predisposing factor.
Topics: Adult; Aged; Aminocaproates; Aminocaproic Acid; Angiography; Animals; Cerebral Ventricles; Dogs; Fem | 1979 |
Pre- and postoperative management of cerebral aneurysms.
Topics: Aminocaproic Acid; Brain Edema; Humans; Hydrocephalus; Hypertension; Intracranial Aneurysm; Ischemic | 1979 |
Fibrinolytic activity in blood and cerebrospinal fluid in subarachnoid hemorrhage from ruptured intracranial saccular aneurysm before and during EACA treatment.
Topics: Aminocaproates; Aminocaproic Acid; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Humans; Int | 1978 |
Myopathy associated with epsilon-aminocaproic acid (EACA) therapy. Report of two cases.
Topics: Adult; Aminocaproates; Aminocaproic Acid; Female; Humans; Male; Middle Aged; Muscular Diseases; Suba | 1978 |
The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Cyclohexanecarboxylic Acids; Humans; Int | 1978 |
Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm.
Topics: Aminocaproic Acid; Animals; Antithrombin III; Aprotinin; Basilar Artery; Dogs; Female; Fibrinogen; F | 1985 |
Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Aorta, Thoracic; Bleeding Time; Blood Platelets; Cattle; | 1985 |
Management of aneurysmal subarachnoid hemorrhage.
Topics: Aminocaproic Acid; Humans; Intracranial Aneurysm; Nervous System Diseases; Nicardipine; Nimodipine; | 1988 |
[Preoperative care and treatment of acute subarachnoid hemorrhage].
Topics: Adolescent; Adult; Aged; Aminocaproic Acid; Fibrinolysis; Humans; Middle Aged; Preoperative Care; Re | 1987 |
[The effect of epsilon-aminocaproic acid on hemocoagulation in subarachnoid hemorrhage. Preliminary study].
Topics: Adult; Aged; Aminocaproates; Aminocaproic Acid; Blood Coagulation; Female; Humans; Male; Middle Aged | 1986 |
Long-term prognosis of subarachnoid hemorrhages of unknown etiology.
Topics: Adult; Aged; Aminocaproic Acid; Cerebral Angiography; Female; Follow-Up Studies; Humans; Hypertensio | 1985 |